About Event:

Digital health technologies have the potential to revolutionize medicine, shifting the focus from reactive treatment to proactive prevention of acute illness. Although many of these technologies have existed for up to 30 years, adoption has been slow. The primary reason is there are few accepted digital biomarkers that indicate whether a person is getting better or worse — let alone identify when an intervention is recommended. Validating a digital biomarker can be a huge task. The biomarker must be shown to reliably measure every application in every population where it will be employed. Often thousands of people must be monitored over an extended period to validate a single digital biomarker for a single condition. But that is not the only challenge. Currently, most of the scientific work on this issue is conducted in highly tailored studies tying a specific biomarker to a specific condition in a specific population and often to the action of a specific therapeutic. As a result, the Digital Medicine Society’s Library of Digital Endpoints aka biomarkers now has more than 70 distinct measures of activity and 55 measures of . Healthcare providers cannot be expected to apply dozens of different measures of essentially the same phenomenon. These need to be standardized. All together, these challenges may seem insuperable. The featured speakers believe these challenges can be overcome by leveraging real-world data and reusing existing data, so the benefits of digital medicine can finally be reaped. This webinar will cover: What to look for in digital biomarkers What it takes to validate a digital biomarker Why real-world data are critical to this effort A case study showing how to reuse existing data to validate an open-source digital biomarker Key success factors to enable reuse of data Regulatory and clinical decision-making factors Patient privacy issues Attendees looking to develop andor validate digital biomarkers will find this webinar very informative. Register today to learn more about creating digital biomarkers with real-world and existing data.